Rheumatoid Arthritis

Rheumatoid Arthritis (Rabeximod)

Rabeximod is a well-tolerated, orally available Phase 2 candidate drug that selectively targets the inflammatory macrophage – the central orchestrator of the inflammatory process – opening up for treatment in the early as well as later stages of rheumatoid arthritis.

Rheumatoid arthritis (RA) patients suffer from debilitating symptoms such as swollen joints, severe pain and stiffness, fever and fatigue, with severe negative consequences on their quality of life. A particular feature of RA is the irreversible destruction of joint tissue by the immune system, in particular by inflammatory macrophages. For decades, the first line treatment has been methotrexate, a drug that has hard-to-manage tolerability issues. As the disease worsens, many patients require infusions or injections of biological drugs. Biologics are often effective but carry safety and side-effect risks. These are potentially followed by JAK inhibitors, a new class of oral drugs which have been well received but they also have safety risks and are generally positioned as a second or third-line treatment.

Cyxone is developing Rabeximod, a well-tolerated, orally available Phase 2 candidate drug with a unique mechanism of action. Rabeximod selectively targets the inflammatory macrophage, a type of white blood cell which is the central orchestrator of the inflammatory process that causes tissue destruction and clinical symptoms in RA. Combined with the convenience of oral administration and a beneficial tolerability profile, this opens up for treatment in the early as well as later stages of the disease. It is believed to be particularly effective at onset and relapses of RA, with good potential to prevent joint destruction and progression of the disease.

Preclinical
Phase 1
Phase 2
Phase 3
Rheumatoid Arthritis

Project status and next steps

  • Rabeximod has been extensively studied in Phase 1 and Phase 2 clinical trials. Safety studies reveal a favorable safety profile compared to anti-RA drugs such as anti-TNFα monoclonal antibodies and oral JAK inhibitors
  • Cyxone is currently optimizing the development program for Rabeximod in RA and plans to initiate the next clinical study in the latter part of 2021
  • Cyxone intends to partner or out-license the project, to a company with the resources for late stage development and commercialization
  • Several new patents have recently been filed that extend the patent life and exclusivity period of Rabeximod to 2043 when granted, as well as increase the therapeutic scope of the drug candidate